Cathepsin K is a lysosomal cysteine protease that is a pharmacological target for the treatment of osteoporosis. Previous studies showed that basic, lipophilic cathepsin K inhibitors are lysosomotropic and have greater activities in cell-based assays against cathepsin K, as well as the physiologically important lysosomal cysteine cathepsins B, L and S than expected on the basis of their potencies against these isolated enzymes.
MOL #39511

Introduction
The CA1 family of human papain-like cysteine proteases comprises 11 members.
These enzymes are collectively known as cathepsins, a name which is derived from the Greek, kathepsein, to digest. Being largely lysosomal enzymes, cathepsins have acidic pH activity and stability optima. These enzymes are synthesised as preproenzymes, the mature proteins sharing between 25 and 80% sequence identity (Lecaille et al., 2002; Turk et al., 2003) . Cathepsin K (Cat K) is highly and somewhat specifically expressed in osteoclasts, the multinucleated giant cells of hematopoietic origin that are responsible for the normal physiological process of bone resorption. Cat K destroys the organic fraction of bone, through its potent collagenase activity, this process taking place in the acidic pit between the osteoclast and the bone surface and also intracellularly within lysosomes of the osteoclast (Saftig et al., 1998) . A large volume of genetic and pharmacological data points to a pivotal role for Cat K in bone resorption and Cat K inhibitors are presently being evaluated in clinical trials as a treatment of osteoporosis, a disease characterised by an imbalance of bone resorption over bone formation (performed by osteoblasts) (Deaton and Tavares, 2005; Grabowskal et al., 2005; Yasuda et al., MOL #39511 5 We have previously shown that members of a basic nitrogen-containing class of reversible α -aminoacetonitrile Cat K inhibitors, such as L-006235 and balicatib ( Fig. 1) demonstrate lysosomotropic behaviour Falgueyret et al., 2005) . These basic compounds concentrate in acidic subcellular organelles of isolated cells and in rat tissues with high lysosome content, such as the lung, liver, kidney and spleen. Members of this class of Cat K inhibitors show significantly increased potencies in cell-based assays against both Cat K and the off-target family members Cat B, L and S, compared to potencies against isolated enzymes (Falgueyret et al., 2004; Falgueyret et al., 2005; Black and Percival, 2006) . In contrast, non-basic α -aminoacetonitrile Cat K inhibitors do not accumulate in lysosomes and their potencies are generally similar, or weaker, in whole cells compared to purified enzyme assays. The increased cellular activity of basic inhibitors was therefore attributed to their ability to concentrate within lysosomes, where both target and anti-target cathepsins are localised Falgueyret et al., 2005) . For unexplained reasons, examples of basic and non-basic Cat K inhibitors show similar Cat K activities in both a functional cell-based bone resorption assay and in an in vivo model of bone resorption, suggesting that the basic inhibitors suffer from a loss of functional selectivity in vivo .
The studies described herein were performed to determine whether the basic nitrogen-containing Cat K inhibitors L-006235 and balicatib ( Fig.1) show evidence of greater off-target activities in vivo than non-basic analogues, as was suggested by previous in vitro studies (Falgueyret et al., 2005; Black and Percival, 2006) . The profiles of these inhibitors were compared with that of a non-basic Cat K inhibitor, L-873724
( Fig.1 ) (Li et al., 2006) . We examined whether chronic treatment of rats with a high dose MOL #39511 6 of these Cat K inhibitors caused a perturbation of tissue enzyme levels compared to vehicle-treated animals. Since any effect of the basic inhibitors could be due to lysosomal alkalinisation, rather than direct inhibition of lysosomal protease activities, we also profiled an inactive analogue of L-006235, Cmpd A (Fig. 1) . In order to directly examine the off-target cathepsin activities of these inhibitors in vivo, we developed an enzyme occupancy assay in which the radiolabelled, non-selective, cysteine cathepsin tissue lysates were divided in two and protease inhibitors were added to that used for western blot analysis. Tissues lysates were diluted to 1 mg/mL with homogenization buffer and enzyme activities were carried out using 5-10 µg of protein. Assays were performed in the 96-well plate format and the plates read using a Gemini EM (Molecular Devices) plate reader (λ ex = 355 nm, λ em = 460 nm). Cat B activity was measured using 50 mM Mes, pH 5.5, 2.5 mM DTT and 2.5 mM EDTA and 50 µM Z-Arg-Arg-AMC as a selective substrate. Determination of Cat L activity was made in the same buffer as Cat B, using 10 µM of Z-Leu-Arg-AMC as substrate. To eliminate any contribution from other cysteine proteases, the assay were performed in two steps; first in presence of 5 µM Ca-O74 (selective Cat B inhibitor), then in presence of 5 µM Ca-074 plus 20 nM Z-PheTyr-CHO (selective Cat L inhibitor). Cat L activity was obtained by subtracting the rate obtained in presence of Ca-074 + Z-Phe-Tyr-CHO from the rate obtained with Ca-074.
Cat D activity was measured at 37º C in 50 mM Gly-HCl, pH 3.5 using 10 µM Ac-GluThis article has not been copyedited and formatted. The final version may differ from this version. Asp(EDANS)-Lys-Pro-Ile-Leu-Phe-Phe-Arg-Leu-Gly-Lys(DABCYL)-Glu-NH 2 in presence of 10 µM E64 (λ ex = 349 nm, λ ex =487 nm). β-N-Acetylglucosaminidase (NAGA) activity was measured using N-methyl umbelliferyl-N-acetyl-β-Dglucosamidine as substrate (Arai et al., 1991; SELLINGER et al., 1960) . The acid phosphatase assay was carried out at 37º C in 90 mM acetate buffer pH 5.0 using 8 mM p-nitrophenyl phosphate as substrate. Following 20 min incubation, the activity was stopped by adding NaOH and the absorbance measured at 410 nm. Succinate dehydrogenase activity was assayed as described (Davis and Bloom, 1973) .
Western blot analysis of rat tissue lysates. Tissue lysates were diluted to 3 mg/mL in Laemmli sample buffer. Samples were heated at 95º C and 25 µL was loaded on Tris- Ponceau red staining of the membranes showed that total THP-1 cellular protein levels
were not affected by Cmpd B treatment. The membranes were blocked with 5% milk TBS-0.1% Tween 20 (TBST) for 1 h then probed with goat anti-Cat S (Santa Cruz, sc-6505, diluted 1:200 in 3% milk TBST) for 1 h. Blots were washed 3 x 10 min with TBST, followed by incubation with anti-goat IgG Horseradish Peroxidase-conjugated antibody diluted 1:3000 in 3% milk TBST for 1 h and washed again as described.
Detection was performed using ECL plus reagent (Amersham) and chemiluminescence captured using a Fuji CCD camera. Blots were stripped with Restore Western Blot Stripping Buffer (Pierce) and exposed to Biomax MS film for quantification (Falgueyret et al., 2004) .
Mouse in vivo enzyme occupancy assay. C57BL/6 mice (male, 4 weeks, ~22 g, fasted, 3-4 animals per group) were dosed orally with test compounds (10-60 mg/kg, dose vol. 10 mL/kg using 1% methocel suspensions) or vehicle. After 1 or 2 h, the mice were spleen and kidney lysates of L-006235 and balicatib-treated animals were significantly increased compared to those animals treated with vehicle. Cat L activities in liver, spleen and kidney were most affected, with increases in activities ranging from 22 to 80-fold over vehicle-treated animals ( Table 3 ). The activity of the lysosomal aspartyl protease Cat D in these tissues was also significantly increased by both L-006235 and by balicatib, but the magnitude was generally to a lower degree than that found for Cat B and L. Only small and often non-significant increases in the lysosomal enzyme activities of Nacetylgalactosaminidase (NAGA) and acid phosphatase (Acid P) were observed with animals treated with L-006235 and balicatib. By contrast, no significant changes in enzyme activities across all tissues were noted for the non-basic L-873724-treated animals, with the exceptions of a 1.5-fold increase in liver Cat B activity and minor changes in NAGA activities in liver and kidney (Table 3 ). The basic, inactive cathepsin inhibitor Cmpd A caused small, but significant increases in liver Cat B and NAGA and brain cortex Cat D, but increases were not observed in other tissues (Table 3) . Only very minor changes in the activity of the mitochondrial enzyme succinate dehydrogenase (Succ Dehyd) were detected for all four compounds tested.
To further investigate the apparently large increases in Cat B and L activities in L-006235 and balicatib-treated animals, western blots were performed with antibodies against mature Cat B and L using tissue lysates from inhibitor and vehicle-treated animals. Consistent with the enzyme activity increases, Cat B and L protein levels in the kidney (Fig. 2, A Fig. 2 A) , as well as the spleen, liver, brain (data not shown). Processing of the single to the two chain form of Cat B, both of which are catalytically active, is blocked in mice deficient for the lysosomal cysteine protease legumain (Shirahama-Noda et al., 2003) and in cells by the non-selective cysteine protease inhibitors E64d and leupeptin (Hara et al., 1988) . In this study, the ratio of these two species was not affected by cathepsin inhibitor treatment ( Fig. 2 A) . Only a single form of mature Cat L was detected in the kidney ( Messenger RNA analysis of rat tissues showed that treatment for 4 weeks with L-006235 and Cmpd A had no significant effect on Cat K, B and L gene expression in the kidney, forebrain, liver and spleen (Fig. 3) . These results also demonstrate the low degree of Cat K expression in these tissues, compared to the relatively highly expressed Cat B and Cat L.
Correlation between cathepsin S inhibition and protein stabilisation in THP-1 cells.
This article has not been copyedited and formatted. The final version may differ from this version. This cell-permeable ABP was previously shown to specifically label Cat B, K, L and S in intact human and rabbit cells (Falgueyret et al., 2004) . Following separation of cell lysate proteins by SDS-PAGE and transfer to nitrocellulose, Cat S protein was detected by western blotting and 125 I-labelled proteins were detected by autoradiography (Fig 4) . The radioactive band and immunoreactive Cat S comigrate, confirming the expression of Cat S in this cell line. A close correlation was observed between the degree of Cat S inhibition, as assessed by competition of Cat S-labelling by the ABP (Fig. 4 A, C) , and the increase in Cat S protein in the THP-1 cells (Fig. 4 B 1991), whereas Cat S distribution is restricted, with highest levels in spleen, lung and heart (Shi et al., 1994) . No signal was obtained that corresponded with Cat K, consistent with the relatively low degree of expression of this gene in these tissues, as demonstrated by the results of Fig. 3 (Rantakokko et al., 1996) . Cmpd B, the non-basic selective Cat S This article has not been copyedited and formatted. The final version may differ from this version. were also observed in an ovariectomized rhesus monkey model of bone resorption at doses of 3 mg/kg/d . Data for balicatib in a preclinical model of bone resorption has not been published, although higher exposures may be required for efficacy as it is 5 to 20-fold weaker than L-006235 against rabbit Cat K in enzyme and cell-based bone resorption assays (Falgueyret et al., 2005) . The chronic rat studies described here were therefore performed at supratherapeutic doses with Cmax values and This article has not been copyedited and formatted. The final version may differ from this version. exposures of L-006235 and L-873724 on the order of 25-300 times that required for efficacy in rabbits (Table 2) .
These chronic rat studies revealed that treatment with the basic Cat K inhibitors L-006235 and balicatib caused large increases in Cat L activity, and to a lesser extent Cat B activity and protein levels in a number of tissues. On the other hand, no consistent perturbation of these tissue enzymes was caused by chronic treatment with a supratherapeutic dose of the non-basic L-873724 (Table 3 , Fig. 2 ), despite similar compound exposures and potencies against these purified enzymes ( Table 1 ). The increases in tissue Cat B and Cat L levels occurred in the absence of increased message (Fig. 3) . Previous reports have shown that both non-selective, non-basic cysteine cathepsin inhibitors (Montenez et al., 1994; Kominami et al., 1987) and lysosomotropic compounds, such as chloroquine (Gerbaux et al., 1996; Gerard et al., 1988) , induce an increase of cathepsin and other lysosomal protein levels in both isolated cells and in vivo.
The formation of a protein-ligand complex often results in protein stabilisation towards thermal and chaotropic agent denaturation (Kleanthous et al., 1991) , as well as protease susceptibility (Tawa et al., 2004) . That this can occur in the cases of cysteine cathepsins is supported by the coincidence of EC 50 values for inhibition and protein increase of Cat S in THP-1 cells treated with the non-basic selective Cat S inhibitor Cmpd B (Fig. 4) . Thus, the results described here imply that off-target inhibition of Cat B and L by balicatib and L-006235 result in the lysosomal accumulation of these cathepsins due to their stabilisation to proteolysis. Only balicatib and L-006235 cause this phenomenon because their lysosomotropic properties cause them to concentrate within the lysosomes to attain levels which inhibit the Cat B and L which are localised within these organelles.
This article has not been copyedited and formatted. The final version may differ from this version. (Table 1) . These results suggest that inhibitor binding to Cat B and L blocks their autolysis and that the increased level of the other enzymes reflects a lowering of lysosomal protease activities. The targeting of the lysosomes by these inhibitors is demonstrated by the small effect on the activity of the cytosolic enzyme succinate dehydrogenase (Table 3) . Interestingly, a reduction in tissue levels of pro-Cat L was detected in L-006235 and balicatib-treated animals ( Fig. 2 C) which may reflect an increased activation of this zymogen in response to inhibition of mature Cat L activity by these compounds.
Off-target activity of Cat K inhibitors was assessed in mice directly by competition with the cysteine cathepsin ABP [ 125 I]-BIL-DMK. The drug doses used in these studies were designed to provide approximately equal tissue levels for each of the three Cat K inhibitors and the inactive analogue (Fig. 6 ) to enable a direct comparison of their off-target activities. Plasma levels of L-006235 in mice were approximately 2-fold higher than that providing efficacy in the rabbit Schenk model of bone resorption (~ 1 uM (Pennypacker et al., 2006) ), whereas plasma levels of L-873724 exceeded that providing efficacy by approximately 22-fold (0.75 uM (Pennypacker et al., 2006) ).
Competition of [ 125 I]-BIL-DMK labelling of Cat B, L and S by L-006235 and balicatib
was observed in each tissue tested (Fig. 7) . However, although the plasma level of L-873724 in mice was 8-fold greater than that of L-006235 and balicatib, and bulk tissue levels were equivalent (Fig. 6 ), no competition of Cat B, L and S labelling in tissues by L-873724 was detected (Fig. 7) .
In summary, evidence of in vivo off-target Cat B, L and S inhibition of the basic Cat K inhibitors L-006235 and balicatib was obtained in rats and mice. This off-target This article has not been copyedited and formatted. The final version may differ from this version. activity in rats was found at the equivalent of a supratherapeutic dose, whereas in mice, inhibitor plasma levels only several fold higher than that predicted to provide efficacy also showed off-target activity. The non-basic Cat K inhibitor L-873724 has similar, and in many cases greater activities against isolated Cat B, L and S compared to L-006235 and balicatib (Table 1) . However, in neither in vivo study did L-873724 show evidence of off-target activity, although plasma and tissue levels and exposures were similar or greater than those of the basic inhibitors in both studies.
Balicatib has been reported to cause incidences of skin rashes and skin scleroderma, a form of fibrosis and has been withdrawn from human osteoporosis clinical trials (Adami et al., 2006) . Cat K, B and L are each expressed in human skin fibroblasts and it is possible that these adverse events result from the concurrent inhibition of these three collagenolytic enzymes, resulting in a pathological increase in matrix proteins. This phenomenon may occur because of the tendency of balicatib to concentrate in lysosomes where these enzymes are localised. On the basis of this study, inhibition of off-target lysosomal cysteine cathepsins by L-873724, or structurally-related non-basic Cat K inhibitors may not be expected, even at doses many fold higher than that required for efficacy. The tissues (liver, spleen, kidney and lung) were rapidly collected and homogenized in the presence of E64. Tissue lysate proteins were separated on SDS-PAGE gels which were subjected to autoradiography. Each lane represents a sample of a tissue lysate from a single mouse. This article has not been copyedited and formatted. The final version may differ from this version. 
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